首页> 美国卫生研究院文献>Experimental and Therapeutic Medicine >Levels of microRNA-181b and plasminogen activator inhibitor-1 are associated with hypertensive disorders complicating pregnancy
【2h】

Levels of microRNA-181b and plasminogen activator inhibitor-1 are associated with hypertensive disorders complicating pregnancy

机译:microRNA-181b和纤溶酶原激活物抑制剂1的水平与妊娠期高血压疾病相关

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The aim of the present study was to explore the association between the expression of microRNA (miRNA)-181b and plasminogen activator inhibitor-1 (PAI-1) in the placental tissue of pregnant females with a hypertensive disorder complicating pregnancy (HDCP). Placental tissue samples were obtained from 48 patients with HDCP and 40 females with a normal pregnancy. The levels of miRNA-181b and PAI-1 mRNA were determined by the reverse transcription-quantitative polymerase chain reaction (RT-qPCR). The expression of PAI-1 protein was analyzed by western blotting. Vascular smooth muscle cells (VSMCs) were transfected with the pEGP-miRNA-181b plasmid using Lipofectamine® 2000. Transfection efficiency was confirmed by immunohistochemical analysis. The levels of miRNA-181b in the placental tissue of patients with HDCP were lower than those in the control group, whereas the levels of PAI-1 mRNA in the placental tissue of patients with HDCP were higher than those in the control group. The expression of the PAI-1 protein in the HDCP group was higher than that in the control group. Following transfection of VSMCs with plasmid pGCMV/EGFP/miRNA-181b, the levels of PAI-1 mRNA were reduced while the levels of miRNA-181 were upregulated. Furthermore, the expression levels of PAI-1 protein were lower than those in the control group. The levels of miRNA-181b and PAI-1 mRNA were strongly associated with HDCP. Thus, miRNA-181b may play an important role in the regulation of PAI-1. PAI-1 and miRNA-181b may be novel biomarkers to be used in HDCP therapy.
机译:本研究的目的是探讨在妊娠合并高血压(HDCP)的妊娠女性的胎盘组织中,microRNA(miRNA)-181b与纤溶酶原激活物抑制剂-1(PAI-1)的表达之间的关系。胎盘组织样本取自48例HDCP患者和40例正常妊娠的女性。通过逆转录定量聚合酶链反应(RT-qPCR)测定miRNA-181b和PAI-1 mRNA的水平。通过蛋白质印迹分析PAI-1蛋白的表达。 pEGP-miRNA-181b质粒采用Lipofectamine ® 2000转染血管平滑肌细胞(VSMC)。免疫组织化学分析证实了转染效率。 HDCP患者胎盘组织中miRNA-181b的水平低于对照组,而HDCP患者胎盘组织中PAI-1 mRNA的水平高于对照组。 HDCP组PAI-1蛋白的表达高于对照组。用质粒pGCMV / EGFP / miRNA-181b转染VSMC后,PAI-1 mRNA的水平降低,而miRNA-181的水平上调。此外,PAI-1蛋白的表达水平低于对照组。 miRNA-181b和PAI-1 mRNA的水平与HDCP密切相关。因此,miRNA-181b可能在PAI-1的调节中起重要作用。 PAI-1和miRNA-181b可能是用于HDCP治疗的新型生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号